| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | $3.0M-92.6% | $40.4M-46.9% | $76.1M-57.4% | $178.7M-38.8% | $291.9M+192.3% | $99.9M+61.6% | $61.8M |
| Accounts receivable | $1.8M+349.9% | $407K-98.4% | $25.8M+842.6% | $2.7M+80.6% | $1.5M+31.2% | $1.2M-92.9% | $16.3M |
| Related party note receivable from MiNK Therapeutics, Inc. | $5.2M | $0 | — | — | — | — | — |
| Prepaid expenses | $785K-66.1% | $2.3M-71.4% | $8.1M-41.4% | $13.8M-32.1% | $20.4M+89.5% | $10.7M+44.8% | $7.4M |
| Assets held for sale | $121.6M | $0 | — | — | — | — | — |
| Other current assets | $1.1M-54.9% | $2.4M+1.8% | $2.4M-25.7% | $3.2M+0.7% | $3.2M+57.8% | $2.0M+97.9% | $1.0M |
| Total current assets | $133.4M+192.8% | $45.6M-59.5% | $112.4M-47.3% | $213.1M-35.8% | $332.0M+191.8% | $113.8M+31.5% | $86.5M |
| Property, plant and equipment, net of accumulated amortization and depreciation of $47,468 and $72,553 at December 31, 2025 and 2024, respectively | $15.5M-87.1% | $120.1M-10.0% | $133.4M+0.3% | $133.0M+121.6% | $60.0M+124.1% | $26.8M+1.8% | $26.3M |
| Operating lease right-of-use assets | $7.7M-71.6% | $27.3M-7.8% | $29.6M-5.3% | $31.3M+0.7% | $31.1M-7.2% | $33.5M+354.6% | $7.4M |
| Goodwill | $24.1M+0.0% | $24.1M-2.6% | $24.7M-2.9% | $25.5M+2.4% | $24.9M-2.3% | $25.5M+9.8% | $23.2M |
| Acquired intangible assets, net of accumulated amortization of $17,325 and $16,986 at December 31, 2025 and 2024, respectively | $3.0M-10.0% | $3.4M-23.5% | $4.4M-29.2% | $6.2M-26.6% | $8.5M-22.0% | $10.9M+3.6% | $10.5M |
| Equity method investment in MiNK Therapeutics, Inc. | $24.3M | $0 | — | — | — | — | — |
| Other long-term assets | $3.3M-43.3% | $5.8M-37.5% | $9.3M+109.7% | $4.5M-53.3% | $9.5M+131.3% | $4.1M+191.0% | $1.4M |
| Total assets | $226.8M+0.2% | $226.3M-27.9% | $313.9M-24.1% | $413.6M-11.2% | $466.0M+117.2% | $214.5M+38.1% | $155.3M |
| Current portion, long-term debt | $44.7M+1555.1% | $2.7M+1747.9% | $146K-74.6% | $575K-21.0% | $728K-12.6% | $833K+28.9% | $646K |
| Current portion, liability related to sale of future royalties and milestones | $109.3M-2.4% | $112.0M-15.5% | $132.5M+58.7% | $83.5M+34.6% | $62.0M+8.2% | $57.4M+24.8% | $46.0M |
| Current portion, deferred revenue | $0-100.0% | $31K+72.2% | $18K-99.9% | $12.3M-1.3% | $12.4M-27.7% | $17.2M-41.1% | $29.2M |
| Current portion, operating lease liabilities | $1.0M-57.7% | $2.4M-5.5% | $2.6M+33.1% | $1.9M-26.0% | $2.6M+34.7% | $1.9M+44.8% | $1.3M |
| Accounts payable | $83.0M+35.0% | $61.5M+0.0% | $61.4M+50.1% | $40.9M+34.3% | $30.5M+79.2% | $17.0M+25.4% | $13.6M |
| Accrued liabilities | $34.2M-2.1% | $35.0M-22.8% | $45.3M+18.4% | $38.3M-9.1% | $42.1M+44.9% | $29.1M-7.3% | $31.3M |
| Liabilities held for sale | $50.7M | — | — | — | — | — | — |
| Other current liabilities | $529K-93.2% | $7.8M-43.8% | $13.9M+21.5% | $11.5M+75.0% | $6.5M+1.0% | $6.5M+3403.2% | $185K |
| Total current liabilities | $323.5M+46.1% | $221.4M-13.5% | $255.9M+35.4% | $189.0M+20.4% | $156.9M+20.8% | $129.9M+6.3% | $122.2M |
| Long-term debt, net of current portion | $0-100.0% | $30.5M+138.7% | $12.8M+1.5% | $12.6M-1.9% | $12.8M-32.1% | $18.9M+41.1% | $13.4M |
| Liability related to sale of future royalties and milestones, net of current portion | $169.7M-24.4% | $224.4M+80.2% | $124.6M-33.7% | $187.8M-2.1% | $191.7M+8.8% | $176.3M+0.5% | $175.4M |
| Deferred revenue, net of current portion | $1.1M+0.0% | $1.1M+0.0% | $1.1M+0.0% | $1.1M-89.8% | $11.2M-60.4% | $28.3M+2.1% | $27.7M |
| Operating lease liabilities, net of current portion | $10.1M-81.5% | $54.6M-12.7% | $62.5M-1.3% | $63.3M+50.4% | $42.1M+23.6% | $34.1M+324.8% | $8.0M |
| Other long-term liabilities | $259K-64.9% | $738K-86.4% | $5.4M-63.1% | $14.7M+832.1% | $1.6M+4.2% | $1.5M-63.9% | $4.2M |
| Common stock, par value $0.01 per share; 800,000,000 shares authorized at December 31, 2025 and 2024; 35,320,397 shares and 23,634,670 shares issued and outstanding at December 31, 2025 and 2024, respectively | $353.00+49.6% | $236.00+19.8% | $197.00-93.6% | $3056.00+19.0% | $2569.00+31.0% | $1961.00+42.3% | $1378.00 |
| Additional paid-in capital | $1.91B+2.9% | $1.86B+3.4% | $1.80B+9.2% | $1.64B+8.2% | $1.52B+20.9% | $1.26B+18.7% | $1.06B |
| Accumulated other comprehensive loss | -$439K+68.6% | -$1.4M-46.4% | -$955K-204.4% | $915K-38.7% | $1.5M-46.2% | $2.8M+309.4% | -$1.3M |
| Accumulated deficit | -$2.18B+0.0% | -$2.18B-11.6% | -$1.96B-14.4% | -$1.71B-14.8% | -$1.49B-1.6% | -$1.47B-14.1% | -$1.28B |
| Total stockholders' deficit attributable to Agenus Inc. | -$271.1M+16.9% | -$326.4M-103.6% | -$160.3M-161.6% | -$61.3M-277.9% | $34.4M+116.9% | -$203.7M+9.6% | -$225.4M |
| Non-controlling interest | -$6.8M-133.8% | $20.0M+67.0% | $11.9M+87.4% | $6.4M-52.7% | $13.5M+272.1% | -$7.8M-30.8% | -$6.0M |
| Total stockholders' deficit | -$277.9M+9.3% | -$306.4M-106.5% | -$148.4M-170.3% | -$54.9M-214.6% | $47.9M+122.7% | -$211.5M+8.6% | -$231.3M |
| Total liabilities, convertible preferred stock and stockholders' deficit | $226.8M+0.2% | $226.3M-27.9% | $313.9M-24.1% | $413.6M-11.2% | $466.0M+117.2% | $214.5M+38.1% | $155.3M |
| Related Parties [Member] | |||||||
| Due from related parties (MiNK Therapeutics, Inc.) | $15.4M | $0 | — | — | — | — | — |
| Series A-1 convertible preferred stock [Member] | |||||||
| Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at December 31, 2025 and 2024; liquidation value of $34,317 and $34,101 at December 31, 2025, and 2024, respectively | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.